Praxis Velocity

From theory to momentum: actionable insight for complex clinical research.

DEA
Registration

Researcher registration, security inspections, quota, and state licensing for Schedule I compounds.

Clinical Trial Operations

End-to-end trial execution, from startup and site activation through monitoring and closeout.

Global Team Leadership

Building and running clinical operations teams across multiple countries and sites.

Bridging the gap between innovative science and regulatory approval

Praxis Velocity focuses on one of the hardest parts of psychedelic drug development, which is getting Schedule I research registered, activated, and moving. With more than 15 years in this space, we help sponsors, CROs, and sites clear the regulatory and operational hurdles that slow trials down.

Our name reflects our mission

praxis embodies our skill and commitment to turning innovative research into real-world impact

velocity represents the focused momentum we bring to life-changing therapies and those who need them.

Praxis Velocity is led by Rebecca Matthews, a clinical operations professional with more than 20 years in clinical trial execution and 15 years in psychedelic research.

She spent nearly a decade at Lykos Therapeutics, formerly MAPS Public Benefit Corporation, most recently as Chief Clinical Operations Officer, where she was part of the team behind the first NDA submission for a Schedule I substance. Rebecca is known for precision, integrity, and steady execution through complex regulatory and operational challenges. She works with sponsors, CROs, and research sites that need Schedule I trials registered, activated, and moving.

Cut DEA Schedule I approval timelines from about 6 months to 30 to 45 days.

Built and scaled global clinical teams from 3 to 60+ members across 8 countries

Led clinical operations for the Phase 3 PTSD trials behind the first Schedule I NDA submission to the FDA

Mentors high-performing teams that consistently deliver results in challenging global environments

We thrive where others hesitate, at the intersection of cutting-edge science, complex regulations, and transformative patient outcomes.

Page updated

Report abuse